HemaCare Scraps Effort to Create Anti-AIDS Plasma
- Share via
HemaCare Corp. said it is quitting its five-year experimental project to develop a blood specialty plasma to help fight AIDS.
The Sherman Oaks-based company said closing the research program will result in a $2.9-million charge against its fourth-quarter earnings. The AIDS project, called Immupath, was conducted through the company’s specialty plasma unit.
HemaCare supplies various blood products and services to blood centers.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
